Amarin fish oil pill gets mixed FDA assessment
A study of Amarin Corp.'s fish oil drug uncovered no new safety risks, though the benefit of expanding use to people with "very high" triglycerides needs to first be weighed against separate studies, U.S. regulators said.
Food and Drug Administration staff made the determination about the prescription-grade omega-3 fatty acid, called Vascepa, in a report posted today. A panel of FDA advisers is scheduled to meet Oct. 16 to discuss expanded approval for the drug to people with only "high" triglycerides, a fat in the blood, who also are using a cholesterol-lowering statin.
- Share Facebook Twitter
Article sent to (required)E-mail
Article sent from (required)E-mail Name
Subject Line (article title)
Message (optional)Success - Article sent Click to close
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.Need more information about reprints? Visit our Reprints Section for more details.
Contact information ( * required )Name * Company Telephone * E-mail *
Article InformationTitle URL
Message (optional)Success - Reprint request sent Click to close